Translational research is usually taken to mean the appli-cation of laboratory discovery to
clinical practice. Like languages or enzymes, however, translation is a 2-way street, and in …

For almost 40 years since its discovery in 1953, the mineralocorticoid hormone, aldosterone,
was considered to affect blood volume, and thus blood pressure, by its action to retain …

The recent clinical trials RALES and EPHESUS have shown that mineralocorticoid receptor
(MR) antagonists added to standard of care substantially increase survival and decrease …

Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor
(MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone …

Two clinical trials, the Randomized ALdosterone Evaluation Study (RALES) and the
EPlerenone HEart failure and SUrvival Study (EPHESUS), have recently shown that …

With the enormous advances in our understanding of cellular and molecular biology over
the past 30 years, it is perhaps not surprising that the term 'Translational Research'is …

Large-scale clinical trials have established that mineralo-corticoid receptor (MR) blockade
with spironolactone or eplerenone decreases morbidity and mortality in patients with chronic …

Mineralocorticoid receptor (MR) blockade is effective in reducing total mortality and the
incidence of heart failure in patients with systolic left ventricular dysfunction (SLVD) …

Adecade before aldosterone was isolated and character-ized, Hans Selye showed that
administration of deoxycorticosterone acetate to rats sensitized by salt loading produced a …

Spironolactone and eplerenone are both mineralocorticoid-receptor antagonists. These
compounds block both the epithelial and nonepithelial actions of aldosterone, with the latter …